HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $110 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.9%

Neg 0% Neu 86.9% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $110 price target.